The global cerebral aneurysm management market is expected to garner a market value of US$ 1.56 Billion in 2023 and is expected to accumulate a market value of US$ 2.98 Billion by registering a CAGR of 6.7% in the forecast period 2023 to 2033. Growth of the cerebral aneurysm management market can be attributed to rise in geriatric population and availability of different medications to treat the ailment. The market for cerebral aneurysm management registered a CAGR of 4% in the historical period 2018 to 2022
Cerebral aneurysm management refers to the diagnosis and treatment of cerebral aneurysms, which are weak spots in the blood vessels of the brain that can bulge or burst, leading to bleeding in the brain (also known as a subarachnoid hemorrhage). Cerebral aneurysm management typically involves a combination of medical and surgical techniques to diagnose, treat, and prevent the occurrence of aneurysms. The goals of management include reducing the risk of aneurysm rupture, preventing further bleeding if an aneurysm has ruptured, and minimizing any resulting neurological damage.
Report Attribute
Details
Expected Market Value (2023)
US$ 1.56 Billion
Anticipated Forecast Value (2033)
US$ 2.98 Billion
Projected Growth Rate (2023 to 2033)
6.7% CAGR
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Cerebral Aneurysm Management Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider Future Market Insights- the market for cerebral aneurysm management reflected a value of 4% during the historical period, 2018 to 2022.
Diagnostic techniques for cerebral aneurysms include imaging tests such as computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, and angiograms. Treatment options may include minimally invasive procedures such as endovascular coiling or stenting, or open surgical procedures such as clipping.
Cerebral aneurysm management is a rapidly evolving field, with new diagnostic and therapeutic techniques being developed and refined to improve patient outcomes. Effective management of cerebral aneurysms requires close collaboration between specialists in neurosurgery, neurology, and interventional radiology.
Thus, the market for cerebral aneurysm management is expected to register a CAGR of 6.7% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of Cerebral Aneurysm Management Market?
Availability of various treatments driving the growth of cerebral aneurysm management market
The incidence of cerebral aneurysms is increasing worldwide, which is driving demand for effective management and treatment options. The development of minimally invasive techniques and new devices for the treatment of cerebral aneurysms is driving growth in the market.
Surgical Clipping: Involves the placement of a small metal clip at the base of the aneurysm to block blood flow and prevent rupture.
Endovascular Coiling: A minimally invasive procedure where a coil is inserted into the aneurysm through a catheter to fill the sac and prevent blood flow.
Flow Diverter Stenting: A newer endovascular technique where a stent is placed across the neck of the aneurysm to redirect blood flow and shrink the aneurysm.
Observation: For smaller or stable aneurysms that do not show symptoms, regular imaging and monitoring may be recommended to track any changes.
Aging population and government initiatives increasing demand for treatment of cerebral aneurysm
The aging population is more susceptible to cerebral aneurysms, which is leading to increased demand for management and treatment options. Increased public awareness about the symptoms and consequences of cerebral aneurysms is driving demand for early diagnosis and treatment.
Governments around the world are investing in healthcare infrastructure and encouraging innovation in medical technologies, which is driving growth in the market.
Find your sweet spots for generating winning opportunities in this market.
What are the Challenges Faced by the Cerebral Aneurysm Management Market
High cost along with restricted reimbursement creating obstacles for market growth
The cost of treatment for cerebral aneurysms can be high, which can be a barrier for some patients and healthcare systems. There is a shortage of skilled healthcare professionals trained in the diagnosis and treatment of cerebral aneurysms, which can limit access to care.
Reimbursement for cerebral aneurysm treatments can be limited in some countries, which can impact market growth. Strict regulatory requirements for the approval of new devices and treatments can slow market growth and limit access to innovative solutions. The cerebral aneurysm management market faces competition from alternative treatments, such as surgical clipping and endovascular coiling, which can limit market growth.
Region Wise Insights
Prevalence of Cerebral Aneurysm in North America Creating Lucrative Opportunities for Treatment?
Advanced healthcare infrastructure increasing treatment options for cerebral aneurysm
North America has a high incidence of cerebral aneurysms, which is driving demand for effective management and treatment options. Moreover, it has a technologically advanced healthcare infrastructure, with access to cutting-edge treatments and technologies for the management of cerebral aneurysms.
North America is home to some of the leading companies in the cerebral aneurysm management market, which is driving innovation and growth in the market. Reimbursement policies for cerebral aneurysm treatments are favorable in North America, which is driving demand for treatments and contributing to market growth. In addition, the region has high levels of healthcare spending, which is supporting the growth of the cerebral aneurysm management market. Thus, North America is expected to possess 45% market share for cerebral aneurysm management market in 2023.
Increase in Healthcare Spending Driving Growth of Cerebral Aneurysm Management Market in Europe?
Key market players innovating treatment methods for cerebral aneurysm in Europe
The Europe cerebral aneurysm management market refers to the market for medical devices, procedures, and treatments for the diagnosis and treatment of cerebral aneurysms in the European region. This market is expected to grow due to increasing incidence of cerebral aneurysms and advancements in technology. Major players in the market include Johnson & Johnson, Stryker, Medtronic, Terumo, and others. The market growth may be hindered by factors such as high costs of treatments and a lack of awareness about the condition.
The market for cerebral aneurysm management in Europe is growing due to a combination of factors such as increasing incidence, advancements in technology, growing geriatric population, increasing healthcare spending, and increased awareness about the condition. Thus, Europe is expected to possess 37% market share for cerebral aneurysm management market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-Wise Insights
Availability of Medication Making Hospital Pharmacies a Favorbale Option for Treating Cerebral Aneurysm?
Favorable reimbursement policies are making hospital pharmacies a viable option for treatment
On the basis of distribution channel, cerebral aneurysm management market is categorized into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
The hospital pharmacy segment is expected to dominate the market, driven by the availability of various treatments and diagnostic options for cerebral aneurysm. The presence of healthcare professionals as well as favorable reimbursement policies, further solidify hospital pharmacies as a preferred choice for treatment.
The growth is also encouraged by government initiatives that support the treatment of cerebral aneurysm in hospital pharmacies. The market share of hospitals for cerebral aneurysm is expected to reach 40% in 2023.
Novartis AG, a key player in the cerebral aneurysm management market is emphasizing on investing in extensive research to develop medications that can alleviate the symptoms associated with cerebral aneurysm.
Acadia Pharmaceuticals Inc, another key player in the cerebral aneurysm management market is working with healthcare professionals to develop medications to treat immediate after effects of cerebral aneurysm.
Report Scope
Report Attribute
Details
Market Value in 2023
US$ 1.56 Billion
Market Value in 2033
US$ 2.98 Billion
Growth Rate
CAGR of 6.7% from 2023 to 2033
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
Drug Class
Route of Administration
Distribution Channel
Region
Regions Covered
North America
Latin America
Europe
South Asia
East Asia
Oceania
MEA
Key Countries Profiled
USA
Canada
Brazil
Argentina
Germany
UK
France
Spain
Italy
Nordics
BENELUX
Australia & New Zealand
China
India
ASEAN
GCC
South Africa
Key Companies Profiled
Biogen
Pfizer Inc.
Hoffmann-La Roche Ltd
Merck Sharp & Dohme Corp
Novartis AG
Sanofi
Teva Pharmaceutical Industries Ltd.
Orion Corporation
UCB S.A.
Acadia Pharmaceuticals Inc.
Lundbeck A/S
Mitsubishi Tanabe Pharma Corporation
Customization
Available Upon Request
Key Segments Profiled in the Cerebral Aneurysm Management Market Survey
Drug Class:
Antihypertensives
Antiepileptics
Analgesics
Antiemetics
Antacids
Route of Administration:
Oral
Injectable
Transdermal
Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Region:
North America
Latin America
Europe
South Asia
East Asia
Oceania
MEA
Frequently Asked Questions
How big is the market in 2023?
The market is expected to be valued at US$ 1.5 billion in 2023.
Who are the key market players?
Biogen, Pfizer Inc., and Hoffmann-La Roche Ltd. are key market players.
How is the historical performance of the market?
From 2018 to 2022, the market registered a CAGR of 4.0%.
What opportunities await the market players?
Availability of various treatments to boost the market prospects.
What is the growth forecast for Market?
The market is forecast to register a CAGR of 6.7% through 2033.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Antihypertensives
5.3.2. Antiepileptics
5.3.3. Analgesics
5.3.4. Antiemetics
5.3.5. Antacids
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
6.3.1. Oral
6.3.2. Injectable
6.3.3. Transdermal
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033
7.3.1. Hospital Pharmacy
7.3.2. Retail Pharmacy
7.3.3. Online Pharmacy
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Drug Class
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Route of Administration
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Class
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Route of Administration
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Drug Class
11.2.3. By Route of Administration
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Route of Administration
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Drug Class
12.2.3. By Route of Administration
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Route of Administration
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Drug Class
13.2.3. By Route of Administration
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Route of Administration
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Drug Class
14.2.3. By Route of Administration
14.2.4. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Route of Administration
14.3.4. By Distribution Channel
14.4. Key Takeaways
15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Drug Class
15.2.3. By Route of Administration
15.2.4. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Class
15.3.3. By Route of Administration
15.3.4. By Distribution Channel
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Drug Class
16.1.2.2. By Route of Administration
16.1.2.3. By Distribution Channel
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Drug Class
16.2.2.2. By Route of Administration
16.2.2.3. By Distribution Channel
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Drug Class
16.3.2.2. By Route of Administration
16.3.2.3. By Distribution Channel
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Drug Class
16.4.2.2. By Route of Administration
16.4.2.3. By Distribution Channel
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Drug Class
16.5.2.2. By Route of Administration
16.5.2.3. By Distribution Channel
16.6. United Kingdom
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Drug Class
16.6.2.2. By Route of Administration
16.6.2.3. By Distribution Channel
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Drug Class
16.7.2.2. By Route of Administration
16.7.2.3. By Distribution Channel
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Drug Class
16.8.2.2. By Route of Administration
16.8.2.3. By Distribution Channel
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Drug Class
16.9.2.2. By Route of Administration
16.9.2.3. By Distribution Channel
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Drug Class
16.10.2.2. By Route of Administration
16.10.2.3. By Distribution Channel
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Drug Class
16.11.2.2. By Route of Administration
16.11.2.3. By Distribution Channel
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Drug Class
16.12.2.2. By Route of Administration
16.12.2.3. By Distribution Channel
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Drug Class
16.13.2.2. By Route of Administration
16.13.2.3. By Distribution Channel
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Drug Class
16.14.2.2. By Route of Administration
16.14.2.3. By Distribution Channel
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Drug Class
16.15.2.2. By Route of Administration
16.15.2.3. By Distribution Channel
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Drug Class
16.16.2.2. By Route of Administration
16.16.2.3. By Distribution Channel
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Drug Class
16.17.2.2. By Route of Administration
16.17.2.3. By Distribution Channel
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Drug Class
16.18.2.2. By Route of Administration
16.18.2.3. By Distribution Channel
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Drug Class
16.19.2.2. By Route of Administration
16.19.2.3. By Distribution Channel
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Drug Class
16.20.2.2. By Route of Administration
16.20.2.3. By Distribution Channel
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Drug Class
16.21.2.2. By Route of Administration
16.21.2.3. By Distribution Channel
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Drug Class
17.3.3. By Route of Administration
17.3.4. By Distribution Channel
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Biogen
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Pfizer Inc.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. F. Hoffmann-La Roche Ltd
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Merck Sharp & Dohme Corp.
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Novartis AG
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Sanofi
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Teva Pharmaceutical Industries Ltd.
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Orion Corporation.
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. UCB S.A.
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Acadia Pharmaceuticals Inc.
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.11. H. Lundbeck A/S
18.1.11.1. Overview
18.1.11.2. Product Portfolio
18.1.11.3. Profitability by Market Segments
18.1.11.4. Sales Footprint
18.1.11.5. Strategy Overview
18.1.11.5.1. Marketing Strategy
18.1.12. Mitsubishi Tanabe Pharma Corporation
18.1.12.1. Overview
18.1.12.2. Product Portfolio
18.1.12.3. Profitability by Market Segments
18.1.12.4. Sales Footprint
18.1.12.5. Strategy Overview
18.1.12.5.1. Marketing Strategy
19. Assumptions & Acronyms Used20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 15: Europe Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 16: Europe Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: South Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 19: South Asia Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 20: South Asia Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 23: East Asia Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 24: East Asia Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 26: Oceania Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 27: Oceania Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 28: Oceania Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 30: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 31: MEA Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 32: MEA Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 17: Global Market Attractiveness by Drug Class, 2023 to 2033
Figure 18: Global Market Attractiveness by Route of Administration, 2023 to 2033
Figure 19: Global Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 37: North America Market Attractiveness by Drug Class, 2023 to 2033
Figure 38: North America Market Attractiveness by Route of Administration, 2023 to 2033
Figure 39: North America Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 42: Latin America Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 43: Latin America Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 57: Latin America Market Attractiveness by Drug Class, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Route of Administration, 2023 to 2033
Figure 59: Latin America Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 62: Europe Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 63: Europe Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 69: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 71: Europe Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 72: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 74: Europe Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 77: Europe Market Attractiveness by Drug Class, 2023 to 2033
Figure 78: Europe Market Attractiveness by Route of Administration, 2023 to 2033
Figure 79: Europe Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 80: Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: South Asia Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 82: South Asia Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 83: South Asia Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: South Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 89: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 91: South Asia Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 92: South Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 94: South Asia Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 95: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 96: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 97: South Asia Market Attractiveness by Drug Class, 2023 to 2033
Figure 98: South Asia Market Attractiveness by Route of Administration, 2023 to 2033
Figure 99: South Asia Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033
Figure 101: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 102: East Asia Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 103: East Asia Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 109: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 111: East Asia Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 112: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 114: East Asia Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 115: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 116: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 117: East Asia Market Attractiveness by Drug Class, 2023 to 2033
Figure 118: East Asia Market Attractiveness by Route of Administration, 2023 to 2033
Figure 119: East Asia Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 121: Oceania Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 122: Oceania Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 123: Oceania Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033
Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 128: Oceania Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 129: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 131: Oceania Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 132: Oceania Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 134: Oceania Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 135: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 137: Oceania Market Attractiveness by Drug Class, 2023 to 2033
Figure 138: Oceania Market Attractiveness by Route of Administration, 2023 to 2033
Figure 139: Oceania Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033
Figure 141: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 142: MEA Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 143: MEA Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 148: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 149: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 150: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 151: MEA Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 152: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 153: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 154: MEA Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 155: MEA Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 156: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 157: MEA Market Attractiveness by Drug Class, 2023 to 2033
Figure 158: MEA Market Attractiveness by Route of Administration, 2023 to 2033
Figure 159: MEA Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 160: MEA Market Attractiveness by Country, 2023 to 2033
